La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Mobilicom a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Mobilicom..

Mobilicom (NASDAQ:MOB) Azioni, Catena delle Opzioni

Mobilicom

Mobilicom Ltd is a provider of cybersecurity and smart solutions for drones, robotics & autonomous platforms. As a high-tech company, it designs, develops, and delivers smart solutions targeting global drone, robotics, and autonomous system manufacturers. Its products include OS3 Platform Software, ICE Cybersecurity Software, MCU Mesh Networking, SkyHopper Datalinks, Mobile Ground Control Stations and System Engineering Services.

Mobilicom Limited - American Depositary Shares

Mobilicom Ltd

MobileCoin - United States dollar

Mobius

MOBI724 GLOB SOLUTNS INC by MOBI724 GLOBAL SOLUTIONS INC

Mobi724 Global Solutions Inc

Helium Mobile - United States dollar

M O B A NETWORK AB by M.O.B.A. Network AB

MOBA Network AB

Mobile Lads Corp

MOBIQUITY TECH INC by Mobiquity Technologies, Inc.

Mobiquity Technologies Inc

Mobiquity Technologies Inc Warrants (30/11/2026)

MOBIV ACQUISITION CORP CL A

MOBIV ACQUISITION CORP UNIT 1 CL A & 1 RED WT EXP

Mobiv Acquisition Corp Warrants (31/07/2027)

Mobiv Acquisition Corp

Mobix Labs Inc

WIIM

AAR shares are trading higher after the company reported Q4 financial results and beat its adjusted EPS and revenue estimates.

Shares of JPMorgan Chase &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) came under pressure on Wednesday, even after the company on Tuesday reported <a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/07/46450968/these-analysts-boost-their-forecasts-on-jpmorgan-after-upbeat-q2-earnings">upbeat second-quarter earnings</a>.
The announcement came amid an <a href="https://www.benzinga.com/earnings">exciting earnings season</a>. Here are some key analyst takeaways.
Keefe, Bruyette &amp; Woods On JPMorgan
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/587639e05064ed0001400137/christopher-mcgratty">Analyst Christopher McGratty</a> reiterated an Outperform rating, while lowering the price target from $330 to $327.
JPMorgan's second quarter results reflected "Scale, Consistency, and Deregulation," McGratty wrote in a note. The company's earnings upside was driven by better fees and lower credit costs, somewhat offset by lower net interest income (NII), he added.
Management raised their 2025 NII guidance to around $95.5 billion, from their previous projection of around $94.5 billion, the analyst stated. He raised the earnings estimates for 2025 from $18.00 per share to $19.15 per share to reflect a quarterly beat and stronger fees, and for 2026 from $19.50 per share to $20.00 per share to reflect stronger revenues.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
Goldman Sachs On <a>JPMorgan</a>
Analysts maintained a Buy rating and price target of $336.
JPMorgan reported second-quarter earnings of $5.24 per share, beating the consensus of $4.46 per share, with core earnings of $5.10 per share coming in higher than the consensus of $4.72 per share, the analysts said.
"Despite lower 2Q25 NII and expenses, the company increased the 2025 NII and expense guides, with the net PPNR impact of the NII more than outweighing the expense increase by $500mn," he wrote.
JPMorgan has "substantial excess capital," which it should be able to use for organic and inorganic growth, dividends, and buybacks, the analyst added.
UBS On JPMorgan
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5909e5c1290fa700012c032b/erika-najarian">Analyst Erika Najarian</a> said that JPMorgan's NII missed expectations by 10 cents per share, with the net interest margin coming in 14 basis points lower than expected, Naranjan said. JPM raised its NII ex-markets forecast by $2 billion, and NII firmwide forecast by $1 billion, he added.
"JPM appeared particularly conservative when reflecting Liberation Day effects in 1Q allowance, especially relative to peers," the analyst wrote. Investors are keen to know what JPMorgan intends to do with its "material excess capital," he further stated.
JPM Price Action: JPMorgan Chase shares were down 0.25% at $285.82 on Wednesday, <a href="https://www.benzinga.com/pro/" target="_blank" rel="noreferrer noopener">according to Benzinga Pro</a>.
Read More:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/46111337/micron-ceo-cautions-ai-boom-may-not-be-fully-sustainable-flags-tariff-driven-demand-pull-in"> ETF Playbook For Bank Earnings: Big Bets On Goldman, Morgan Stanley, BofA</a></li>
</ul>
Photo: Rokas Tenys/Shutterstock

Analyst Color

Earnings Beats

Price Target

Reiteration

Analyst Ratings

JPMorgan's Q2 Outperformance Bolsters Confidence In Its 2025 Outlook

United Airlines shares are trading lower after the company lowered FY25 guidance.

BRCC

BRC Announces Proposed Public Offering Of Class A Common Stock; Size Not Disclosed

Rexford Industrial Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REXR#NYSE">REXR</a>) affirms FY2025 FFO guidance from $2.37-$2.41 to $2.37-$2.41 vs $2.40 analyst estimate..

News

Guidance

REXR

Rexford Industrial Realty Affirms FY2025 FFO Guidance of $2.37-$2.41 vs $2.40 Est

Kinder Morgan Affirms FY2025 Adj EPS Guidance of $1.27 vs $1.27 Est

CREV

Carbon Revolution Announces Nasdaq Non-Compliance Letter

Rexford Industrial Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REXR#NYSE">REXR</a>) reported quarterly earnings of $0.59 per share which met the analyst consensus estimate. This is a 1.67 percent decrease over earnings of $0.60 per share from the same period last year. The company reported quarterly sales of $241.568 million which missed the analyst consensus estimate of $248.801 million by 2.91 percent. This is a 3.69 percent increase over sales of $232.973 million the same period last year.

Earnings

Earnings Misses

Rexford Industrial Realty Q2 FFO $0.59, Inline, Sales $241.568M Miss $248.801M Estimate

AAR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIR#NYSE">AIR</a>) reported quarterly earnings of $1.16 per share which beat the analyst consensus estimate of $1.01 by 14.85 percent. This is a 31.82 percent increase over earnings of $0.88 per share from the same period last year. The company reported quarterly sales of $754.500 million which beat the analyst consensus estimate of $695.714 million by 8.45 percent. This is a 14.93 percent increase over sales of $656.500 million the same period last year.

AAR Q4 Adj. EPS $1.16 Beats $1.01 Estimate, Sales $754.500M Beat $695.714M Estimate

Kinder Morgan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMI#NYSE">KMI</a>) reported quarterly earnings of $0.28 per share which beat the analyst consensus estimate of $0.27 by 2.56 percent. This is a 12 percent increase over earnings of $0.25 per share from the same period last year. The company reported quarterly sales of $4.042 billion which beat the analyst consensus estimate of $3.748 billion by 7.86 percent. This is a 13.16 percent increase over sales of $3.572 billion the same period last year.

Kinder Morgan Q2 Adj. EPS $0.28 Beats $0.27 Estimate, Sales $4.042B Beat $3.748B Estimate

SRPT

Sarepta Therapeutics shares are trading higher after the company announced it will engage in strategic restructuring and cost savings.

This morning, I woke up to the sound of pounding rain on the roof of my bus and a generator that made me decide to take the day off. Add in some flash flooding, a Wi-Fi signal riding on Starlink, and it's already been a day to remember.
But even with all that going on, I had to get a story out to you because we've officially entered one of my favorite times of the year: earnings season.
This isn't just any earnings season, either. It's the second quarter (Q2) earnings, when the biggest batch of reports hits. But while most traders are busy guessing whether a stock will beat or miss expectations, we're going to take a different approach.
So today, I want to walk you through how I'm trading earnings this quarter, the patterns I'm spotting, and the stocks I've got on my radar right now.
<h2 class="wp-block-heading">FREE LIVE EVENT: "It's Like NVIDIA at $10 All Over Again"</h2>
Tim Melvin is seeing the same setup that preceded NVIDIA's historic run. For the first time ever, he's partnering with trader Anne-Marie Baiynd to reveal where the next explosive opportunities are hiding. [Get Free Access <a href="https://events2.benzinga.com/next-10x-winner/?utm_campaign=072325-webinar&amp;el=ResearchDaily&amp;he={{email}}&amp;adt_ei={{email}}&amp;utm_adType=SponsorAd&amp;utm_ad=RD071725">HERE</a>]
<h2 class="wp-block-heading">Why Most Traders Blow It on Earnings</h2>
Let's get something out of the way: trading earnings the day before the announcement is a bad idea.
That's what I call "meme trading" or the "Robinhood crowd" mentality. You buy a call because you hope the stock will go up—or a put if you think it'll tank—and hold through earnings. That's a quick way to lose money, even if you're right on direction.
Why? Because of the volatility crush.
Implied volatility usually surges leading into earnings. But once the report drops? Volatility falls off a cliff—often faster than the stock price can move in your favor. That means even if you're "right," you can still lose money because the time premium gets obliterated.
So, what's the better play? Trade the setup, not the outcome.
That means you want to get in one to two weeks before earnings, not the day before. And you want to get out before the report hits, selling to someone else who's willing to pay top dollar for all that pumped-up volatility.
I call it "scalping the implied volatility wave."
Now, if I can pair that volatility ramp with a strong directional pattern, that's where the real edge comes in. Some stocks tend to drift higher (or lower) into earnings like clockwork. And when price and volatility rise together, that's our signal to strike, which brings me to a few setups I've got my eye on.
<h2 class="wp-block-heading">Pan American Silver</h2>
I've been watching Pan American Silver (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAAS#NYSE">PAAS</a>) for a while. Over the last four quarters, PAAS has sold off in the week leading up to earnings, and each time, implied volatility has spiked. That's a textbook setup for put buyers.
Now, earnings aren't coming until August 6, but that gives us time to prepare. I'll be watching closely for the next dip and any IV surge. If we see both, I'll be looking to grab short-term options and ride them for a few days before the announcement.
<h2 class="wp-block-heading">AbbVie</h2>
AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) is the opposite of PAAS. This one has a bullish pattern leading up to earnings, with the stock moving higher ahead of the last few reports. Same deal—volatility ramps, price climbs, and that creates a sweet spot for call options.
Earnings drop on July 30, so again, we've got time. I'll be eyeing this one about 10 days out, especially if we see any early pullbacks that offer a cheaper entry.
<h2 class="wp-block-heading">Why This Matters And What To Do Next</h2>
A lot of traders think earnings are binary: either the stock beats expectations and pops, or it misses and crashes. But that's not how the smart money trades.
We're not gambling on outcomes, we're stacking probabilities.
We're looking for patterns that have played out multiple times, we're aligning with the natural volatility cycle, and we're getting out before the crowd even shows up.
Remember, I track the top 325 stocks every quarter to find these patterns. PAAS and ABBV are just two names with strong historical setups—but they're not the only ones. The more you study these moves, the easier it gets to spot consistent winners.
This week, I'll be running more scans and breaking down a few ETF setups as well (seasonality is back in play). And of course, I'll be keeping one eye on the headlines. After all, even a strong earnings setup can get shaken up by the 24/7 news cycle.
Until then, keep your watchlists tight, your entries clean, and your exits earlier than everyone else.
Editorial content from our expert contributors is intended to be information for the general public and not individualized investment advice. Editors/contributors are presenting their individual opinions and strategies, which are neither expressly nor impliedly approved or endorsed by Benzinga.
Photo: Shutterstock

Opinion

Trading Ideas

ABBV

PAAS

My Top 2 Earnings Picks For This Earnings Season

Executive Leadership Appointments In conjunction with the restructuring, Sarepta announced key executive appointments:
<ul>
<li>Ian Estepan named President and Chief Operating Officer</li>
<li>Louise Rodino-Klapac, Ph.D., named President of Research &amp; Development and Technical Operations</li>
<li>Ryan Wong, named Chief Financial Officer, previously Senior Vice President of Strategic Finance, Treasury, and Investor Relations</li>
<li>Rachael Potter, Ph.D., named Chief Scientific Officer, previously Senior Vice President, Head of Research Sciences</li>
<li>Patrick Moss, Pharm.D., named Chief Commercial Officer, previously Senior Vice President of U.S. Market Access and Sales, succeeding Dallan Murray, Chief Customer Officer, who is leaving Sarepta. The Company thanks Mr. Murray for his long-time service and wishes him well.</li>
</ul>

Management

Sarepta Therapeutics Announces Ian Estepan Named President And Chief Operating Officer; Ryan Wong, Named Chief Financial Officer

United Airlines Sees 6-Point Acceleration In Booking Demand In July; Expects Less Geopolitical, Macroeconomic Uncertainty In H2 2025

MMLP

Martin Midstream Partners Reaffirms FY Adj. EBITDA Guidance Of $109.1M

– After strategic review, Sarepta focuses pipeline on high-impact programs, prioritizing potentially best-in-class siRNA platform assets
– Strategic restructuring includes reduced operating expenses, delivering approximately $400 million in anticipated annual cost savings, and implementing a 36% workforce reduction of approximately 500 employees
– Duchenne portfolio continues to deliver stable and robust revenues, with preliminary quarterly results showing total net product revenue of $513 million for the second quarter 2025
– U.S. FDA has requested and Sarepta has agreed to include a black box warning in the ELEVIDYS label, resolving any material issues with the ambulant population indication
– Sarepta has completed an Expert Committee on a protocol for the use of additional prophylactic immunosuppression for non-ambulant patients, and will submit the protocol to FDA imminently and discuss the pathway to resume shipment of ELEVIDYS for non-ambulant patients
– Company to host investor call on July 16, 2025, at 4:30 p.m. Eastern time
Sarepta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>), the leader in precision genetic medicine for rare diseases, today announced a strategic restructuring plan designed to prioritize high-value, high impact programs, meet its 2027 financial obligations, and support its long-term financial viability. This plan is expected to position the Company for long-term sustainable growth, with an emphasis on near- and mid-term opportunities from the siRNA platform. These decisive changes aim to ensure sustained profitability and preserve the Company's ability to deliver on its mission of advancing innovative medicines for those with rare genetic diseases.

Biotech

General

Sarepta Announces Strategic Restructuring With 36% Workforce Reduction And $400M In Annual Cost Savings, Refocuses Pipeline On siRNA Assets; Reports $513M In Q2 Revenue And Resolving FDA Issues For ELEVIDYS

Martin Midstream Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMLP#NASDAQ">MMLP</a>) reported quarterly losses of $(0.06) per share. This is a 166.67 percent decrease over earnings of $0.09 per share from the same period last year. The company reported $180.676 million in sales this quarter. This is a 2.09 percent decrease over sales of $184.531 million the same period last year.

Martin Midstream Partners Q2 EPS $(0.06) Down From $0.09 YoY, Sales $180.676M Down From $184.531M YoY

MCRI

Monarch Casino & Resort Q2 EPS $1.44 Beats $1.22 Estimate, Sales $136.914M Beat $129.834M Estimate

United Airlines Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>) lowers FY2025 Adj EPS guidance from $11.50-$13.50 to $9.00-$11.00 vs $10.05 analyst estimate..

United Airlines Holdings Lowers FY2025 Adj EPS Guidance from $11.50-$13.50 to $9.00-$11.00 vs $10.05 Est

Across the recent three months, 4 analysts have shared their insights on Monarch Casino &amp; Resort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRI#NASDAQ">MCRI</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $94.5, a high estimate of $105.00, and a low estimate of $81.00. Observing a downward trend, the current average is 2.33% lower than the prior average price target of $96.75. 
<img src="https://www.benzinga.com/files/images/story/2025/1752696064_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Monarch Casino &amp; Resort. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Barry Jonas</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$105.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Chad Beynon</td>
<td>Macquarie</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$92.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Jeffrey Stantial</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$81.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Barry Jonas</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$100.00</td>
<td>$105.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Monarch Casino &amp; Resort. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Monarch Casino &amp; Resort compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Monarch Casino &amp; Resort's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Monarch Casino &amp; Resort's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/MCRI/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Monarch Casino &amp; Resort analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Delving into Monarch Casino &amp; Resort's Background</h2>
Monarch Casino &amp; Resort Inc is engaged in providing the latest gaming, dining, and hospitality amenities. It owns and operates the Atlantis Casino Resort Spa, a hotel/casino facility in Reno, Nevada, and the Monarch Black Hawk Casino in Black Hawk. The company generates the majority of its revenue from Casinos, followed by Food &amp; Beverage and Hotel Operations.
<h3>Financial Insights: Monarch Casino &amp; Resort</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Monarch Casino &amp; Resort displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 3.07%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Discretionary sector.
Net Margin: Monarch Casino &amp; Resort's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 15.84%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Monarch Casino &amp; Resort's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.77% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 2.83%, the company showcases effective utilization of assets.
Debt Management: Monarch Casino &amp; Resort's debt-to-equity ratio is below the industry average at 0.03, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>What Are Analyst Ratings?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

Mobilicom

Mobilicom (MOB) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO